Xspray Pharma
XSPRAY | ST
Overview
Corporate Details
- ISIN(s):
- SE0009973563 (+3 more)
- LEI:
- 549300NGRQCNZ3X4L157
- Country:
- Sweden
- Address:
- Scheeles väg 2, 171 65 Solna
- Website:
- https://xspraypharma.com/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development, the first XS004 dasatinib recently filed with the FDA. Xspray’s strategy is to improve the quality of life for cancer patients by launching improved PKI products with relevant medical benefits and cost effectiveness. Xspray Pharma uses its innovative, patented RightSize™ technology to develop 505(b)(2) improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs), for the treatment of cancer. The segment is the second largest in oncology and where drug prices are very high. Xspray Pharma applies a unique platform technology: - Improves the solubility of the active ingredient - Best-in-class for high dose strength for poorly soluble drugs - Fully amorphous (non-infringing to many crystalline products patents)
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-14 21:10 |
Inside Information Statement
FDA meddelar PDUFA-datum för Xspray Pharmas kompletterade ansökan för Dasynoc®
|
Swedish | 44.6 KB | |
| 2025-05-14 21:10 |
Inside Information Statement
FDA sets PDUFA-date for Xspray Pharma's re-submitted application for Dasynoc®
|
English | 44.1 KB | |
| 2025-05-13 11:03 |
Regulatory News Service
Kommuniké från årsstämma i Xspray Pharma AB (publ)
|
Swedish | 45.5 KB | |
| 2025-05-13 11:03 |
Declaration of Voting Results & Voting Rights Announcements
Bulletin from the annual general meeting of Xspray Pharma AB (publ)
|
English | 44.2 KB | |
| 2025-05-07 08:00 |
Quarterly Report
|
Swedish | 901.4 KB | |
| 2025-05-07 08:00 |
Quarterly Report
|
English | 923.0 KB | |
| 2025-02-12 08:00 |
Annual Report
|
Swedish | 1014.8 KB | |
| 2025-02-12 08:00 |
Annual Report
|
English | 915.1 KB | |
| 2025-01-08 14:31 |
Regulatory News Service
Xspray Pharma ger uppdatering om inlämning av uppdaterad FDA-ansökan
|
Swedish | 44.4 KB | |
| 2024-12-30 17:00 |
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Xspray Pharma after rights issue
|
English | 42.1 KB | |
| 2024-12-30 17:00 |
Declaration of Voting Results & Voting Rights Announcements
Nytt antal aktier och röster i Xspray Pharma efter nyemission
|
Swedish | 42.5 KB | |
| 2024-12-02 12:10 |
Inside Information Statement
Strong interest in Xspray Pharma AB’s rights issue – preliminary outcome is pub…
|
English | 58.8 KB | |
| 2024-12-02 12:10 |
Prospectus
Starkt intresse för Xspray Pharma ABs företrädesemission - preliminärt utfall o…
|
Swedish | 58.5 KB | |
| 2024-08-07 08:02 |
Interim Report
|
Swedish | 715.8 KB | |
| 2024-08-07 08:00 |
Interim Report
|
English | 710.5 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-03-02 | Anders Bladh | Other | Buy | 2,556 | 169,743.96 SEK |
| 2023-03-02 | Robert Molander | Other | Buy | 3,000 | 19,230.00 USD |
| 2023-03-02 | Anders Bladh | Other | Buy | 530 | 35,472.90 SEK |
| 2023-02-28 | Robert Molander | Other | Buy | 2,000 | 12,935.40 USD |
| 2022-11-30 | Anders Bladh | Other | Buy | 50,000 | 2,625,000.00 SEK |
| 2022-08-26 | Anders Bladh | Other | Buy | 1,600 | 100,544.00 SEK |
| 2022-05-23 | Anders Bladh | Other | Buy | 25,000 | 1,522,500.00 SEK |
| 2022-05-13 | Anders Bladh | Other | Buy | 16,569 | 986,186.88 SEK |
| 2022-05-12 | Anders Bladh | Other | Buy | 2,569 | 147,717.50 SEK |
| 2022-05-09 | Anders Bladh | Other | Buy | 38,761 | 2,228,757.50 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Antibiotice S.A. | Romania | ATB | |
|
Aran Research & Development (1982) Ltd. | Israel | ARAN | |
|
Asarina Pharma AB | Sweden | ASAP |